Blood Test: A Breakthrough in Early Detection of Alzheimer’s Disease

HPX24h > Science > Blood Test: A Breakthrough in Early Detection of Alzheimer’s Disease

The latest breakthroughs in medicine have brought tremendous hope to millions of families worldwide, as a blood test can detect early signs of Alzheimer’s disease up to 10 years before the first symptoms appear. A groundbreaking study from King’s College London and the Medical Research Council (MRC) of the United Kingdom, published in the journal Alzheimer’s & Dementia in 2023, shows that the reduction of a particular protein in the blood – called PGRN (progranulin) – can predict the early onset of Mild Cognitive Impairment (MCI), often a precursor to Alzheimer’s disease. “This protein reduction not only predicts cognitive decline but also closely correlates with abnormalities in brain structure,” the study confirms.

The significance of this discovery becomes even clearer when viewed in a global context. According to a report from the World Health Organization (WHO) released in 2023, Alzheimer’s currently affects 55 million people worldwide, and this number could rise to 139 million people by 2050. While traditional diagnostic methods are only performed when symptoms are apparent, detecting the disease at an early, asymptomatic stage could completely change the approach to treatment. Professor Tara Spires-Jones from the University of Edinburgh emphasized in the journal The Lancet Neurology: “Detecting the disease at an asymptomatic stage is of immense significance, as it not only enables early intervention but also slows the progression of the disease.”

Not only does this blood test offer a diagnostic breakthrough, but it also opens up the possibility for personalized treatment. High-risk individuals, such as those with the APOE4 gene (associated with Alzheimer’s risk), could be closely monitored and receive preventive measures early. Dr. Rosa Sancho from the Alzheimer’s Research UK shared in the annual report of 2023: “A deeper understanding of blood biomarkers like PGRN will play a foundational role in the development of more effective treatments.”

“When we understand the nature of these biomarkers, we can optimize disease prediction, thereby minimizing Alzheimer’s impact on society,” quoted from research by the Alzheimer’s Association, published in the journal JAMA Neurology in 2023.

This invention is also a powerful testament to the collaboration between technology and medicine in addressing humanity’s greatest challenges. From a simple blood test, scientists have been able to uncover the complex relationship between biological factors and brain function, paving the way for groundbreaking therapies in the future. With advances like these, science not only saves lives but also improves the quality of life for millions of people.